Advertisement

Contemporary Approaches to Vaccination Against Herpes Simplex Virus

  • R. L. Burke
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 179)

Abstract

The task of writing a comprehensive review on the subject of herpes simplex virus (HSV) vaccines is daunting. Instead, this review will cover selected points of recent interest. Others have reviewed the topic more broadly (Meignier 1985; Hall and Katrak 1986; Dix 1987; Stanberry 1991) or deait with selected aspects such as recombinant vaccines (Watson and Enquist 1985) or subunit HSV vaccines (Stanberry 1990).

Keywords

Genital Herpes Subunit Vaccine Recombinant Vaccinia Virus Contemporary Approach Recurrent Genital Herpes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams SE, Dawson KM, Gull K, Kingsman SM, Kingsman AJ (1987) The expression of hybrid HIV: Ty virus-like particles in yeast. Nature 329: 68PubMedCrossRefGoogle Scholar
  2. Anderson FD, Ushijima RN, Larson CL (1974) Recurrent herpes genitalis: treatment with Mycobacterium bovis (BCG). Obstet Gynaecol 43: 797Google Scholar
  3. Anderson SG, Hamilton J, Williams S (1950) An attempt to vaccinate against herpes simplex. Aust J Exp Biol Med Sci 28: 579PubMedCrossRefGoogle Scholar
  4. Arbeter AM, Starr SE, Weibel RE, Plotkin SA (1986) Varicella vaccine studies in healthy children and adults. Pediatrics 78: 748–756PubMedGoogle Scholar
  5. Ashley R, Benedetti J, Corey L (1985a) Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol 17: 153–166PubMedCrossRefGoogle Scholar
  6. Ashley R, Mertz G, Clark H, Schick M, Salter D, Corey L (1985b) Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 56: 475–481PubMedGoogle Scholar
  7. Ashley R, Mertz GJ, Corey L (1987) Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol 61: 264–268PubMedGoogle Scholar
  8. Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER (1988) Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex type 2 in guinea pigs. J Infect Dis 157(5): 897–902PubMedCrossRefGoogle Scholar
  9. Bierman SM (1976) BCG immunoprophylaxis of recurrent herpes genitalis. Arch Dermatol 112:1410PubMedCrossRefGoogle Scholar
  10. Blacklaws BA, Krishna S, Minson AC, Nash AA (1990) Immunogenicity of herpes simplex virus type I glycoproteins expressed in vaccinia virus recombinants. Virology 177: 727–736PubMedCrossRefGoogle Scholar
  11. Bonneau RH, Jennings SR (1988) Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity. J Virol 63:1480–1484Google Scholar
  12. Brain RT (1936) Biological therapy in virus diseases. Br J Dermatol Syph 48: 21CrossRefGoogle Scholar
  13. Brynestad K, Babbit B, Huang L, Rouse BT (1990) Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1–23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J Virol 64: 680–685PubMedGoogle Scholar
  14. Burke KL, Dunn G, Ferguson M, Minor PD, Almond JW (1988) Antigen chimeras of poliovirus. Nature 332:81PubMedCrossRefGoogle Scholar
  15. Burke RL (1991) Development of a herpes simplex virus subunit vaccine for prophylactic and therapeutic use. Rev Infect Dis 13 (Supplement 11): 5906–5911CrossRefGoogle Scholar
  16. Burke RL, Van Nest G, Carlson J et al. (1989a) Development of a herpes simplex virus subunit vacci ne. Vacci nes 89: 337–382Google Scholar
  17. Burke RL, Van Nest G, Gervase B et al. (1989b) Development of an HSV subunit vaccine: effect of adjuvant composition and antigen dose. In: Meheus A, Spier RE (eds) Vaccines for sexually transmitted diseases. Butterworth, Stoneham, pp 191–196Google Scholar
  18. Burke RL, Hartog K, Croen KD, Ostrove JM (1991) Detection and characterization of latent HSV RNA by in situ and northern blot hybridization in guinea pigs. Virology 181: 793–797PubMedCrossRefGoogle Scholar
  19. Cantin EM, Eberle R, Baidick JL, Moss B, Willey DE, Notkins AL, Openshaw H (1983) Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal HSV-1 challenge. Proc Natl Acad Sci USA 80: 7155–7159CrossRefGoogle Scholar
  20. Cappel R, Sprecher S, de Cuyper F (1982) Immune responses to DNA free herpes simplex proteins in man. Dev Biol Stand 52: 345–350PubMedGoogle Scholar
  21. Cappel R, Sprecher S, DeCuyper F, DeBraekeleer J (1985) Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol 16:137–145PubMedCrossRefGoogle Scholar
  22. Clements JD (1989) Use of attenuated mutants of Salmonella as vaccine vectors. Vaccines 89: 283–290Google Scholar
  23. Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B (1985) Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228: 737–740PubMedCrossRefGoogle Scholar
  24. Dix RD (1987) Prospects for a vaccine against herpes simplex virus types 1 and 2. Prog Med Virol 34: 89–128PubMedGoogle Scholar
  25. Dix RD, Mills J (1985) Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. J Med Virol 1785: 9–18CrossRefGoogle Scholar
  26. Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, Fahnlander A, Remington M, Winter C, Corey L (1984) A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 310:1551–1556PubMedCrossRefGoogle Scholar
  27. Douglas JM, Vontver A, Stamm WM, Reeves WC, Critchlow C, Remington ML, Holmes KK, Corey L (1985) Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother 27: 203PubMedGoogle Scholar
  28. Dundarov S, Andonov P, Bakalov B, Nechev K, Tomov C (1982) Immunotherapy with inactivated polyvalent herpes vaccines. Dev Biol Stand 52: 351–358PubMedGoogle Scholar
  29. Eberle R, Mou S-W, Zaia JA (1985) The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections. J Med Virol 16:147–162PubMedCrossRefGoogle Scholar
  30. Eisenberg RJ, Cerini CP, Heilman CJ, Joseph AD, Dietzschold B, Golub E, Long D, Ponce de Leon M, Cohen GH (1985) Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol 56:1014–1017PubMedGoogle Scholar
  31. Erturk M, Jennings R, Hockley D, Potter CW (1989) Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations. J Gen Virol 70:2149–2156PubMedCrossRefGoogle Scholar
  32. Forrester AJ, Sullivan V, Simmons A, Blacklaws BA, Smith GL, Nash AA, Minson AC (1991) Induction of protective immunity with antibody to herpes simplex virus type I glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus. J Gen Virol 72: 369–375PubMedCrossRefGoogle Scholar
  33. Foster PD, Abshier AB (1937) Smallpox vaccine in treatment of recurrent herpes. Arch Dermatol Syphl 36:294Google Scholar
  34. Frank SB (1938) Formolised herpes virus therapy and the neutralising substance in herpes simplex. J Invest Dermatol 1: 267CrossRefGoogle Scholar
  35. Freifeld AG, Savarese B, Krause PR, Paar D, Adair S, Tigges MA, Burke RL, Straus SE (1990) Phase I testing of a recombinant herpes simplex type 2 glycoprotein D vaccine. Interscience conference on antimicrobials and chemotherapeutics 722 (abstract)Google Scholar
  36. Frenchick PJ, Sabara MIJ, Babiuk LA (1989) Use of a viral nucleocapsid particle as a carrier for synthetic peptides. Vaccines 89: 479–484Google Scholar
  37. Frenkel LM, Dillon M, Garratty E, Bryson Y, Hackeil J, Cawein A, Abramovitz A, Miskin E (1990) A randomized double blind, placebo-controlled phase I, trial of a herpes simplex virus purified glycoprotein (gDI) vaccine. Interscience conference on antimicrobials and chemotherapeutics 721 (abstract)Google Scholar
  38. Freund H (1928) Beitráge zue Kenntnis von Herpes und Zoster. Arch Dermatol Syphilol 155: 282CrossRefGoogle Scholar
  39. Fuller AO, Santos RE, Spear PG (1989) Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration. J Virol 63: 3435–3443PubMedGoogle Scholar
  40. Geerlings HJ, Weijer WJ, Welling GW, Welling-Wester S (1989) The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9–21 of herpes simplex virus type 1 glycoprotein D. J. Immunol Methods 124: 95–102CrossRefGoogle Scholar
  41. Gompels U, Minson A (1986) The properties and sequence of glycoprotein H of herpes simplex virus type 1. Virology 153: 230–247PubMedCrossRefGoogle Scholar
  42. Hall MJ, Katrak K (1986) The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine 4:138–149PubMedCrossRefGoogle Scholar
  43. Heber-Katz E, Valentine S, Dietzschold B, Burns-Purzycki C (1988) Overlapping T cell antigenic sites on a synthetic peptide fragment from herpes simplex virus glycoprotein D, the degenerate MHO restriction elicited, and functional evidence for antigen-la interaction. J Exp Med 167: 275–287PubMedCrossRefGoogle Scholar
  44. Hilfenhaus J, Christ H, Kohler R, Moser H, Kirchner H, Levy HB (1981) Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence. Med Microbiol Immunol 169: 225–235PubMedCrossRefGoogle Scholar
  45. Ho RJY, Burke RL, Merigan TC (1989) Antigen presenting liposomes are effective in treatment of recurrent herpes simplex genitalis in guinea pigs. J Virol 63: 2951–2958PubMedGoogle Scholar
  46. Ho RJY, Burke RL, Merigan TC (1990) Physical and biological characterization of antigen presenting liposome formulations: relative efficacy for the treatment of recurrent genital HSV-2 in guinea pigs. Antiviral Res 13: 187–200PubMedCrossRefGoogle Scholar
  47. Javier RT, Sedarati F, Stevens JG (1986) Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science 234: 746–748PubMedCrossRefGoogle Scholar
  48. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB (1989) A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 Infection in the United States. N Eng J Med 321: 7–12CrossRefGoogle Scholar
  49. Kern AB, Schiff BL (1964) Vaccine therapy in recurrent herpes simplex. Dermatologica 89: 844–845Google Scholar
  50. Kino Y, Nozaki C, Nakatake H, Mizuno K, Mori R (1989) Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast. Vaccine 7:155–160PubMedCrossRefGoogle Scholar
  51. Kit S (1982) Problems and progress in the development of vaccines against genital herpes. Infect Dis 12: 4–9Google Scholar
  52. Klein RJ, Buimovici-Klein E, Moser H, Moucha R, Hilfenhaus J (1981) Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice. Arch Virol 68: 73–80PubMedCrossRefGoogle Scholar
  53. Krishna S, Blacklaws BA, Overton HA, Bishop DHL, Nash AA (1989) Expression of glycoprotein D of herpes simplex virus type 1 in a recombinant baculovirus protective responses and T cell recognition of the recombinant-infected cell extracts. J Gen Virol 70:1805–1814PubMedCrossRefGoogle Scholar
  54. Kutinová L, Vonka V, Šlicktová V (1980) Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus. Acta Virol 24: 391–398PubMedGoogle Scholar
  55. Kutinová L, Šlichtova V, Vonka V (1982) Subviral herpes simplex vaccine. Dev Biol Stand 52: 313–319PubMedGoogle Scholar
  56. Kutinová L, Benda R, Kaloš Z, Dhalý V, Votruba T, Kvičalová E, Petroská P, Doutllk S, Kamlnková J, Demorázková E, Bergmanová V, Krčmár M, Suchánková A, Neměčková S, Vonka V (1988) Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 6: 223–228PubMedCrossRefGoogle Scholar
  57. Larson VM, Lehman ED (inventors) (1983) Herpes subunit vaccine. US patent 4,374,127. Merck & Co. Inc, assignee. Feb 15, 16 p. Int CL3A61K 39/245Google Scholar
  58. Lebkowski JS, McNally MM, Okarma TB, Lerch LB (1988) Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol 8: 3988–3996PubMedGoogle Scholar
  59. Martin S, Rouse BT (1987) The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. J Immunol 138:3431–3437PubMedGoogle Scholar
  60. Martin S, Moss B, Berman PW, Laskey LA, Rouse BT (1987) Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells. J Virol 61: 726PubMedGoogle Scholar
  61. Martin S, Cantin E, Rouse BT (1989) Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type I glycoproteins. J Gen Virol 70:1359–1370PubMedCrossRefGoogle Scholar
  62. Martin S, Zhu XX, Silverstein SJ, Courtney RJ, Yao F, Jenkins FJ, Rouse BT (1990) Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICPO. J Gen Virol 71: 2391–2399PubMedCrossRefGoogle Scholar
  63. McDermott MR, Smiley JR, Brais PLJ, Rutzroga HE, Brenenstock J (1985) Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 51: 747–753Google Scholar
  64. McDermott MR, Graham FL, Hanke T, Johnson DC (1989) Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169: 244–247PubMedCrossRefGoogle Scholar
  65. McLaughlin-Taylor E, Wiley DE, Cantin EM, Eberle R, Moss B, Openshaw H (1988) A recombinant vaccinia virus expressing herpes simplex virus type 1 glycoprotein B induces cytotoxic T lymphocytes in mice. J Gen Virol 69:1731 Meignier B (1985) Vaccination against herpes simplex virus infections. In: Roizman B, Lopez C (eds) Herpesviruses, vol 4. Plenum, New York, pp 265–296Google Scholar
  66. Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B (1987a) Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J Infect Dis 155: 921–931PubMedCrossRefGoogle Scholar
  67. Meignier B, Longnecker R, Roizman B (1987b) Construction and in vivo evaluation of two genetically engineered prototypes of live attenuated herpes simplex virus vaccines. Vaccines 87: 368–373Google Scholar
  68. Meignier B, Longnecker R, Roizman B (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158: 602–614PubMedCrossRefGoogle Scholar
  69. Meignier B, Martin B, Whitley RJ, Roizman B (1990) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 162: 313–321PubMedCrossRefGoogle Scholar
  70. Mertz GJ, Peterman G, Ashley R, Jourden JL, Salter D, Morrison L, McLean A, Corey L (1984) Herpes simplex virus type 2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis 150: 242–249PubMedCrossRefGoogle Scholar
  71. Mertz GJ, Jones CC, Mills J, Fife KH, Lehrman SN, Stapleton JT, Hill EL, Davis G, and the Acyclovir Study Group (1988) Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 260: 201–206PubMedCrossRefGoogle Scholar
  72. Mertz GJ, Benedetti J, Ashley R, Selke S, Corey L (1992) Risk factors for the sexual transmission of genital herpes. Ann Int Med (in press)Google Scholar
  73. Muggeridge Ml, Roberts SR, Isola VJ et al. (1990) Herpes simplex virus. In: Van Regenmortel MHV, Neuraht AR (eds) Immunochemistry of viruses, II. The basis for serodiagnosis and vaccines. Elsevier, New York, pp 459–481Google Scholar
  74. Muniu EM, Durham J, Shariff D, Hartley CE, Fuller A, Meiling J, Wiblin C, Wilkins G, Buchan A, Skinner GRB (1987) Antibody reactivity with Skinner HSV vaccine. Med Microbiol Immunol (Berl) 176: 315–327CrossRefGoogle Scholar
  75. Nasemann T (1976) Herpes simplex type II vaccine: the favorable European experience. Int J Dermatol 15: 587–588PubMedCrossRefGoogle Scholar
  76. Paoletti E, Lipinskas BP, Samsonoff C, Mercer S, Panicali D (1984) Construction of live vaccines using genetically engineered poviruses: biological activity of vaccinia virus recombinants expressing the hepatitus B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 81: 193–197PubMedCrossRefGoogle Scholar
  77. Parr D, Savarese B, Burke RL, Margolis D, Meier J, Markoff L, Ashley R, Corey L, Adair S, Dekker C, Straus SE (1991) Ability of a recombinant herpes simplex virus type 2 glycoprotein D vaccine to induce antibody titers comparable to those following genital herpes. Clin Res 39: 216AGoogle Scholar
  78. Sanchez-Pescador L, Burke RL, Ott G et al. (1988a) A comparison of adjuvant efficacy for a recombinant herpes simplex glycoprotein vaccine. In: Lasky L, Fox CF (eds) Technological advances in vaccine development. Academic, New York, pp 455–469Google Scholar
  79. Sanchez-Pescador L, Burke RL, Ott G, Van Nest G (1988b) The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol 141: 1720–1727PubMedGoogle Scholar
  80. Schmersahl P, Rudiger G (1975) Behandlungsergebnisse mit dem Herpes simplex-Antigen Lupidon H bzw. Lupidon G. Z Hautarzt 50: 105Google Scholar
  81. Skinner GRB, Woodman CBJ, Hartley CE, Buchan A, Fuller A, Durham J, Synnott M, Clay JC, Meiling J, Wiblin C, Wilkins J (1982a) Preparation and immunogenicity of vaccine Ac NFU1 (S) MRC towards the prevention of herpes genitalis. Br J Venerol Dis 58: 381–386Google Scholar
  82. Skinner GRB, Woodman CBJ, Hartley CE, Buchan A, Fuller A, Wilblin C, Wilkins G, Melling J (1982b) Early experience with “antigenoid” vaccine Ac Nfu1 (S) MRC towards prevention or modification of herpes genitalis. Dev Biol Stand 52: 333–344PubMedGoogle Scholar
  83. Skinner GRB, Fink CG, Cowan M, Buchan A, Fuller A, Hartley CE, Durham J, Wiblin C, Melling J (1987) Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol (Berl) 176:161–168CrossRefGoogle Scholar
  84. Skinner GRB, Fink CG, Durham J et al. (1989) Follow-up report on 101 subjects vaccinated with Skinner herpes vaccine. In: Meheus A, Spier RE (eds) Vaccines for sexually transmitted disease. Butterworths, London, pp 202–207Google Scholar
  85. Snapper SB, Lugosi L, Jekkel A, Melton RE, Kieser T, Bloom BR, Jacobs WR Jr (1988) Lysogeny and transformation in mycobacteria: stable expression of foreign genes. Proc Natl Acad USA 85:6987–6991CrossRefGoogle Scholar
  86. Spear PG (1984) Glycoproteins specified by herpes simplex viruses. In: Roizman B (ed) Herpesviruses. Plenum, New YorkGoogle Scholar
  87. Stanberry LR (1990) Subunit viral vaccines: prophylactic and therapeutic use. In: Aurelian L (ed) Herpesviruses, the immune system and aids. Kluwer Academic, Norwell, pp 309–341CrossRefGoogle Scholar
  88. Stanberry LR (1991) Herpes simplex virus vaccines. In: Feigin RD, Glezen WP (eds) Update on immunization: progress in vaccine development. Semin Pediatr Infect Dis 2:178–185Google Scholar
  89. Stanberry LR, Bernstein Dl, Burke RL, Pachl C, Myers MG (1987) Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155: 914–920PubMedCrossRefGoogle Scholar
  90. Stanberry LR, Burke RL, Meyers MG (1988) Herpes simplex virus glycoprotein treatment of recurrent genital disease. J Infect Dis 157:156–163PubMedCrossRefGoogle Scholar
  91. Stanberry LR, Harrison CJ, Bernstein Dl, Burke RL, Shukla R, Ott, G, Myers MG (1989) Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencng efficacy. Antiviral Res 11: 203–214PubMedCrossRefGoogle Scholar
  92. Straus SE, Takiff HE, Seidlin M, Bachrach S, Lininger L, DiGiovanna JJ, Wester KA, Smith HA, Lehrman SN, Creagh-Kirk T, Ailing DW (1984) Suppression of frequently recurring genital herpes. A placebo controlled double-blind trial of oral acyclovir. N Engl J Med 310:1545–1550PubMedCrossRefGoogle Scholar
  93. Sullivan V, Smith G (1987) Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody. J Gen Virol 68: 2587–2598PubMedCrossRefGoogle Scholar
  94. Thompson RL, Nakashizuka M, Stevens JG (1986) Vaccine potential of a live avirulent herpes simplex virus. Microb Pathog 1: 409–416PubMedCrossRefGoogle Scholar
  95. Tigges MA, Koelle D, Hartog K, Sekulovich RE, Corey L, Burke RL (1992) Human CD8+ herpes simplex virus-specific cytotoxic T lymphocyte clones recognize diverse virion protein antigens. J Virol (in press)Google Scholar
  96. Valenzuela P, Coit D, Medina-Selby MA, Kuo CH, Van Nest G, Burke RL, Bull P, Urdea MS, Graves PV (1985) Antigen engineering in yeast: synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex 1 gD particles. Bio/Technology 3: 323–326CrossRefGoogle Scholar
  97. Wachsman M, Aurehian L, Smith CC, Lipinskas BR, Perkus ME, Poaietti E (1987) Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. J Infect Dis 155(6): 1188–1197PubMedCrossRefGoogle Scholar
  98. Watson RJ, Enquist LW (1985) Genetically engineered herpes simplex virus vaccines. Prog Med Virol 31:84–108PubMedGoogle Scholar
  99. Watson RJ, Weis JH, Salstrom JS, Enquist LW (1982) Herpes simplex virus, type 1-glycoprotein D gene. Nucleotide sequence and expression in Escherichia coli. Science 218: 381–384PubMedCrossRefGoogle Scholar
  100. Weir JP, Bennett M, Allen EM, Elkins KL, Martin S, Rouse BT (1989) Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 70: 2587–2594PubMedCrossRefGoogle Scholar
  101. Woodman CBJ, Buchan A, Fuller A, Hartley C, Skinner GRB, Stocker D, Sugrue D, Clay JC, Wilkins G, Wiblin C, Melling J (1983) Efficacy of vaccine Ac Nfu1 (S) MRC given after an initial clinical episode in the prevention of herpes genitalis. Br J Venerol Dis 59: 311–313Google Scholar
  102. Zarling JM, Moran PA, Brewer L, Ashley R, Corey L (1988) Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine. J Virol 62: 4481–4485PubMedGoogle Scholar
  103. Zweerink HJ, Martinez D, Lynch RJ, Stanton LW (1981) Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections. Infect Immun 31: 267–275PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin, Heidelberg 1992

Authors and Affiliations

  • R. L. Burke
    • 1
  1. 1.Chiron CorporationEmeryvilleUSA

Personalised recommendations